Comparative Pharmacology
Head-to-head clinical analysis: SULLA versus TERFONYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULLA versus TERFONYL.
SULLA vs TERFONYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
TERFONYL is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial DNA replication.
100 mg orally once daily, increased to 200 mg daily if needed.
2 g intravenously every 12 hours over 24 hours for susceptible infections.
None Documented
None Documented
6-12 hours; prolonged in renal impairment (up to 30 hours)
Terminal elimination half-life is 2.5-4 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl < 30 mL/min).
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Renal excretion accounts for 70-90% of elimination as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal excretion constitutes 10-30%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic